NCT00826449View on ClinicalTrials.gov

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Lung CancerNon-Small Cell Lung Cancer
Interventions
DRUG

Dasatinib

Starting dose of 70 mg by mouth daily for 21 day cycle.

DRUG

Erlotinib

150 mg by mouth daily every 21 day cycle.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

OSI Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER